Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details Narrative) |
1 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
May 09, 2019
USD ($)
shares
|
Nov. 12, 2018
USD ($)
|
Oct. 12, 2018
USD ($)
|
Oct. 05, 2018
USD ($)
shares
|
Sep. 06, 2017
shares
|
May 10, 2019
USD ($)
|
May 10, 2019
USD ($)
|
May 09, 2019
USD ($)
shares
|
Oct. 09, 2018
USD ($)
|
Oct. 05, 2018
USD ($)
shares
|
Jun. 28, 2018
shares
|
Sep. 06, 2017
shares
|
Mar. 30, 2015
shares
|
Dec. 31, 2019
USD ($)
integer
$ / shares
shares
|
Dec. 31, 2018
USD ($)
shares
|
Jun. 30, 2019
shares
|
Sep. 30, 2019
shares
|
Jan. 29, 2019
$ / shares
shares
|
Sep. 30, 2018
USD ($)
shares
|
Jun. 30, 2018
USD ($)
$ / shares
shares
|
Jun. 30, 2017
shares
|
|
| Share based compensation | $ | $ 374,000 | $ 516,000 | |||||||||||||||||||
| Restricted stock awards | $ | $ 216,000 | ||||||||||||||||||||
| Treasury stock outstanding | 659,448 | 228,218 | 228,218 | 0 | |||||||||||||||||
| Total cumulative cost | $ | $ 146,000 | $ 91,000 | $ 0 | ||||||||||||||||||
| Unrecognized compensation cost related to unvested restricted stock-based compensation | $ | $ 300,000 | ||||||||||||||||||||
| Compensation cost not yet recognized, period for recognition | 1 year 2 months 1 day | ||||||||||||||||||||
| Expected share based compensation expenses | $ | $ 200,000 | ||||||||||||||||||||
| Stock options to purchase shares, value | $ | 22,000 | ||||||||||||||||||||
| Shares award expense | $ | $ 11,000 | 6,000 | |||||||||||||||||||
| Options vested or expected to vest | 50,000 | ||||||||||||||||||||
| Preferred stock, shares outstanding (in shares) | 0 | 0 | |||||||||||||||||||
| Stock option expenses | $ | $ 158,000 | $ 2,000 | |||||||||||||||||||
| Proceeds from issuance of shares | $ | $ 1,116,000 | ||||||||||||||||||||
| Preferred stock shares issued | 0 | 0 | 0 | ||||||||||||||||||
| Beginning balance, Shares | |||||||||||||||||||||
| Proceeds from warrant exercises | $ | $ 1,152,000 | ||||||||||||||||||||
| Proceeds from issuance of warrants | $ | 2,384,000 | ||||||||||||||||||||
| Employees [Member] | |||||||||||||||||||||
| Stock option Granted | 19,260,424 | ||||||||||||||||||||
| Dr Krishna Menon [Member] | |||||||||||||||||||||
| Expired | 18,000,000 | ||||||||||||||||||||
| Warrant [Member] | |||||||||||||||||||||
| Granted | |||||||||||||||||||||
| Exercised | |||||||||||||||||||||
| Additional Three year [Member] | |||||||||||||||||||||
| Options vested or expected to vest | 50,000 | ||||||||||||||||||||
| Stock option expenses | $ | $ 0 | 8,000 | |||||||||||||||||||
| Granted | 50,000 | ||||||||||||||||||||
| Stock options granted value | $ | $ 35,000 | ||||||||||||||||||||
| June 1, 2018 [Member | Additional Three year [Member] | |||||||||||||||||||||
| Options vested or expected to vest | 12,500 | ||||||||||||||||||||
| June 1, 2018 [Member | |||||||||||||||||||||
| Options vested or expected to vest | 12,500 | ||||||||||||||||||||
| Number of installments | integer | 4 | ||||||||||||||||||||
| December 1, 2018 [Member] | |||||||||||||||||||||
| Options vested or expected to vest | 12,500 | ||||||||||||||||||||
| December 1, 2018 [Member] | Additional Three year [Member] | |||||||||||||||||||||
| Options vested or expected to vest | 12,500 | ||||||||||||||||||||
| June 1, 2019 [Member] | |||||||||||||||||||||
| Options vested or expected to vest | 12,500 | ||||||||||||||||||||
| June 1, 2019 [Member] | Additional Three year [Member] | |||||||||||||||||||||
| Options vested or expected to vest | 12,500 | ||||||||||||||||||||
| December 1, 2019 [Member] | |||||||||||||||||||||
| Options vested or expected to vest | 12,500 | ||||||||||||||||||||
| December 1, 2019 [Member] | Additional Three year [Member] | |||||||||||||||||||||
| Options vested or expected to vest | 12,500 | ||||||||||||||||||||
| Common Class A [Member] | |||||||||||||||||||||
| Common stock shares issued | 219,211,111 | 202,860,141 | 163,103,927 | ||||||||||||||||||
| Beginning balance, Shares | 187,575,318 | 163,103,927 | |||||||||||||||||||
| Common Class A [Member] | 30 Million Common Stock Purchase Agreement [Member] | Aspire Capital Fund LLC [Member] | |||||||||||||||||||||
| Stock issued during period, shares | 300,000 | 160,000 | |||||||||||||||||||
| Stock issued during period, shares | 300,000 | 160,000 | |||||||||||||||||||
| Series B [Member] | |||||||||||||||||||||
| Proceeds from warrant exercises | $ | $ 2,700,000 | $ 2,700,000 | |||||||||||||||||||
| Stock issued during period, shares | |||||||||||||||||||||
| Series B [Member] | Series 1-3 warrants [Member] | |||||||||||||||||||||
| Purchase of warrants | 7,720 | 8,000,000 | |||||||||||||||||||
| Preferred stock shares reserved for future issuance | 7,720 | ||||||||||||||||||||
| Series B [Member] | Series 1-2 warrants [Member] | |||||||||||||||||||||
| Rights and preferences of preferred stock description | Series 3 warrant, which entitles the holder thereof to purchase 1.50 shares of preferred stock at $982.50 per share, or 3,000 shares of preferred stock in the aggregate for approximately $2.9 million in aggregate exercise price, for a period of up to 24 months following issuance | Series 3 warrant, which entitles the holder thereof to purchase 1.50 shares of preferred stock at $982.50 per share, or 3,000 shares of preferred stock in the aggregate for approximately $2.9 million in aggregate exercise price, for a period of up to 24 months following issuance | |||||||||||||||||||
| Proceeds from warrant exercises | $ | $ 245,625 | $ 300,000 | $ 2,730,000 | $ 500,000 | $ 1,200,000 | ||||||||||||||||
| Purchase shares of Series B preferred stock | 6,528 | ||||||||||||||||||||
| Exercised | 2,780 | ||||||||||||||||||||
| Exercised | 1,192 | ||||||||||||||||||||
| Series B [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||||||
| Purchase of warrants | 7,720 | ||||||||||||||||||||
| Series B [Member] | Securities Purchase Agreement [Member] | Series 1 warrant [Member] | |||||||||||||||||||||
| Rights and preferences of preferred stock description | Series 1 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance | Series 1 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance | |||||||||||||||||||
| Series B [Member] | Securities Purchase Agreement [Member] | Series 2 warrant [Member] | |||||||||||||||||||||
| Rights and preferences of preferred stock description | Series 2 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to 15 months following issuance | Series 2 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to 15 months following issuance | |||||||||||||||||||
| Series B [Member] | Securities Purchase Agreement [Member] | Series 4 warrant [Member] | |||||||||||||||||||||
| Proceeds from issuance of shares | $ | $ 2,000,000 | $ 2,000,000 | |||||||||||||||||||
| Preferred stock shares issued | 100 | 100 | |||||||||||||||||||
| Rights and preferences of preferred stock description | The Series 4 warrant entitles the holder thereof to purchase 2,500 shares of preferred stock at $982.50 per share for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance. In addition, the Company extended the termination date for the Series 1 warrants by six months, and agreed to issue one additional share of preferred stock to the Series B investors for each five shares issued upon the exercise of the existing warrants or Series 4 warrants through November 9, 2019, up to a maximum of 400 shares of preferred stock. | The Series 4 warrant entitles the holder thereof to purchase 2,500 shares of preferred stock at $982.50 per share for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance. In addition, the Company extended the termination date for the Series 1 warrants by six months, and agreed to issue one additional share of preferred stock to the Series B investors for each five shares issued upon the exercise of the existing warrants or Series 4 warrants through November 9, 2019, up to a maximum of 400 shares of preferred stock. | |||||||||||||||||||
| Additional shares of preferred stock | 2,500 | 2,500 | |||||||||||||||||||
| Common Class B [Member] | |||||||||||||||||||||
| Common stock shares issued | 909,090 | 909,090 | 0 | ||||||||||||||||||
| Common Class B [Member] | Mr. Ehrlich [Member] | |||||||||||||||||||||
| Common stock shares issued | 909,090 | 909,090 | 0 | ||||||||||||||||||
| Exercise price | $ / shares | $ 0.11 | ||||||||||||||||||||
| Series 1-4 [Member] | Securities Purchase Agreement [Member] | Series 3 warrant [Member] | |||||||||||||||||||||
| Preferred stock, shares outstanding (in shares) | 6,528 | ||||||||||||||||||||
| Preferred stock shares issued | 1,192 | ||||||||||||||||||||
| Rights and preferences of preferred stock description | Series 3 warrant, which entitles the holder thereof to purchase 1.50 shares of preferred stock at $982.50 per share, or 3,000 shares of preferred stock in the aggregate for approximately $2.9 million in aggregate exercise price, for a period of up to 24 months following issuance | Series 3 warrant, which entitles the holder thereof to purchase 1.50 shares of preferred stock at $982.50 per share, or 3,000 shares of preferred stock in the aggregate for approximately $2.9 million in aggregate exercise price, for a period of up to 24 months following issuance | |||||||||||||||||||
| Proceeds from warrant exercises | $ | $ 1,152,000 | ||||||||||||||||||||
| Stock options [Member] | |||||||||||||||||||||
| Granted | 790,826 | 1,195,826 | |||||||||||||||||||
| Expired | (387,165) | (19,260,424) | |||||||||||||||||||
| Stock And Warrant [Member] | Securities Purchase Agreement [Member] | Aspire Capital Fund LLC [Member] | |||||||||||||||||||||
| Stock issued during period, shares | 8,000,000 | ||||||||||||||||||||
| Black-Scholes-Merton [Member] | |||||||||||||||||||||
| Share based compensation | $ | $ 465,000 | $ 677,000 | |||||||||||||||||||
| Granted | 1,195,826 | 1,175,826 | |||||||||||||||||||
| Expired | (19,260,424) | (187,500) | |||||||||||||||||||
| Warrants exercisable period | 2 years 4 days | ||||||||||||||||||||
| Investor [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||||||
| Proceeds from issuance of warrants | $ | $ 7,900,000 | ||||||||||||||||||||
| On September 1, 2019 [Member] | Ms. Harness [Member] | |||||||||||||||||||||
| Restricted shares issued | 58,394 | ||||||||||||||||||||
| Vested shares | 58,394 | ||||||||||||||||||||
| Taxable share based compensation | $ | $ 1,222 | ||||||||||||||||||||
| Common stock shares issued | 48,775 | 163,103,927 | |||||||||||||||||||
| Remaining common stock shares withheld | 9,619 | ||||||||||||||||||||
| Stock option exercise price | $ / shares | $ 0.13 | ||||||||||||||||||||
| On September 1, 2018 [Member] | |||||||||||||||||||||
| Share based compensation | $ | $ 14,000 | $ 26,000 | |||||||||||||||||||
| Stock option expenses | $ | 11,000 | 9,000 | |||||||||||||||||||
| Proceeds from issuance of shares | $ | 1,116,000 | ||||||||||||||||||||
| Stock awards | $ | $ 3,000 | $ 17,000 | |||||||||||||||||||
| On June 28, 2018 [Member] | Warrant [Member] | |||||||||||||||||||||
| Proceeds from issuance of shares | $ | $ 2,000,000 | $ 2,000,000 | |||||||||||||||||||
| Beginning balance, Shares | 2,000 | 2,000 | |||||||||||||||||||
| Rights and preferences of preferred stock description | |||||||||||||||||||||
| Purchase of warrants | 8,000,000 | 8,000,000 | |||||||||||||||||||
| Exercise price | 0.38 | 0.38 | |||||||||||||||||||
| Warrants exercisable period | 5 years | 5 years | |||||||||||||||||||
| On June 28, 2018 [Member] | Common Class A [Member] | Securities Purchase Agreement [Member] | Aspire Capital Fund LLC [Member] | |||||||||||||||||||||
| Rights and preferences of preferred stock description | Series 2 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to 15 months following issuance | Series 2 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to 15 months following issuance | |||||||||||||||||||
| Proceeds from issuance of warrants | $ | $ 1,700,000 | ||||||||||||||||||||
| Common stock shares issuable under agreement | 7,000,000 | ||||||||||||||||||||
| On June 30, 2016 [Member] | 2016 Equity Incentive Plan [Member] | |||||||||||||||||||||
| Stock option vested or to be vested, description | Up to 20,000,000 shares of the Company’s Class A common stock may be issued under the 2016 Plan (subject to adjustment as described in the 2016 Plan); provided that (1) no Outside Director (as defined in the 2016 Plan) may be granted awards covering more than 250,000 shares of common stock in any year and (2) no participant shall be granted, during any one year period, options to purchase common stock and stock appreciation rights with respect to more than 4,000,000 shares of common stock in the aggregate or any other awards with respect to more than 2,500,000 shares of common stock in the aggregate. | ||||||||||||||||||||
| Dr. Bertolino [Member] | |||||||||||||||||||||
| Share based compensation | $ | $ 35,000 | $ 13,000 | |||||||||||||||||||
| Stock option expenses | $ | $ 12,000 | 10,000 | |||||||||||||||||||
| Stock options reserved for future issuance | 400,000 | ||||||||||||||||||||
| Stock option exercise price | $ / shares | $ 0.132 | ||||||||||||||||||||
| Stock awards | $ | $ 23,000 | 3,000 | |||||||||||||||||||
| Stock options value reserved for future issuance | $ | $ 30,000 | ||||||||||||||||||||
| Dr. Bertolino [Member] | On September 1, 2019 [Member] | |||||||||||||||||||||
| Restricted shares issued | 1,066,667 | ||||||||||||||||||||
| Vested shares | 1,066,667 | ||||||||||||||||||||
| Taxable share based compensation | $ | $ 53,545 | ||||||||||||||||||||
| Common stock shares issued | 645,056 | 163,103,927 | |||||||||||||||||||
| Remaining common stock shares withheld | 421,611 | ||||||||||||||||||||
| Stock option vested or to be vested, description | These options were issued with an exercise price of $0.13 per share and vest 33 1/3% on February 1, 2019, 33 1/3% on August 1, 2019, and 33 1/3% on January 31, 2020 | ||||||||||||||||||||
| Stock options reserved for future issuance | 400,000 | ||||||||||||||||||||
| Stock option exercise price | $ / shares | $ 0.132 | ||||||||||||||||||||
| Ms. Jane Harness [Member] | On September 1, 2016 [Member] | |||||||||||||||||||||
| Stock option vested or to be vested, description | the Company’s common stock, 33 1/3% vesting upon the first anniversary of the grant date, 33 1/3% upon the second anniversary of the grant date and 33 1/3% upon the third anniversary of the grant date, with acceleration in certain circumstances as provided in the award agreement. | ||||||||||||||||||||
| Salary annual | $ | $ 250,000 | ||||||||||||||||||||
| Restricted stock, shares | 58,394 | ||||||||||||||||||||
| Restricted stock, amount | 80,000 | ||||||||||||||||||||
| Common stock, granted | 172,987 | ||||||||||||||||||||
| Common stock, exercise price | $ / shares | $ 1.26 | ||||||||||||||||||||
| Shares issued, value | $ | $ 220,000 | ||||||||||||||||||||
| Amortization period of restricted stock | 3 years | ||||||||||||||||||||
| Stock awards | $ | $ 5,000 | 3,000 | |||||||||||||||||||
| Ms. Jane Harness [Member] | On September 1, 2018 [Member] | |||||||||||||||||||||
| Share based compensation | $ | 3,000 | 2,000 | |||||||||||||||||||
| Stock option expenses | $ | $ 2,000 | 1,000 | |||||||||||||||||||
| Restricted shares issued | 38,930 | ||||||||||||||||||||
| Taxable share based compensation | $ | $ 3,690 | ||||||||||||||||||||
| Common stock shares issued | 29,658 | 163,103,927 | |||||||||||||||||||
| Remaining common stock shares withheld | 9,772 | ||||||||||||||||||||
| Stock option vested or to be vested, description | of the Company’s common stock, 33 1/3% vesting upon the first anniversary of the grant date, 33 1/3% upon the second anniversary of the grant date and 33 1/3% upon the third anniversary of the grant date, with acceleration in certain circumstances as provided in the award agreement. | ||||||||||||||||||||
| Stock options reserved for future issuance | 172,987 | ||||||||||||||||||||
| Stock option exercise price | $ / shares | $ 0.40 | ||||||||||||||||||||
| Stock awards | $ | $ 1,000 | 1,000 | |||||||||||||||||||
| Stock issued, shares | 58,394 | ||||||||||||||||||||
| Stock issued, value | $ | $ 63,000 | ||||||||||||||||||||
| Vested shares | 58,394 | ||||||||||||||||||||
| Rights and preferences of preferred stock description | Series 1 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance (later extended to 15 months following issuance) | ||||||||||||||||||||
| Closing stock price | $ / shares | $ 0.40 | ||||||||||||||||||||
| Vested shares | 38,930 | ||||||||||||||||||||
| Ms. Jane Harness [Member] | On September 1, 2017 [Member] | Common Class A [Member] | 2016 Equity Incentive Plan [Member] | |||||||||||||||||||||
| Share based compensation | $ | $ 26,000 | 13,000 | |||||||||||||||||||
| Stock option expenses | $ | $ 19,000 | 10,000 | |||||||||||||||||||
| Stock options reserved for future issuance | 172,987 | ||||||||||||||||||||
| Stock awards | $ | $ 7,000 | 3,000 | |||||||||||||||||||
| Stock issued, shares | 58,394 | ||||||||||||||||||||
| Stock issued, value | $ | $ 112,000 | ||||||||||||||||||||
| Vested shares | 58,394 | ||||||||||||||||||||
| Ms. Jane Harness [Member] | On September 1, 2018 [Member] | |||||||||||||||||||||
| Rights and preferences of preferred stock description | Series 1 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance (later extended to 15 months following issuance) | ||||||||||||||||||||
| Two Consultant [Member] | On February 10, 2018 [Member] | Stock options [Member] | |||||||||||||||||||||
| Share based compensation | $ | $ 72,000 | 1,886,000 | |||||||||||||||||||
| Stock options reserved for future issuance | 50,000 | ||||||||||||||||||||
| Stock issued, shares | 75,000 | ||||||||||||||||||||
| Vested shares | 75,000 | ||||||||||||||||||||
| Dr. Arthur Bertolino [Member] | On September 1, 2017 [Member] | Common Class A [Member] | 2016 Equity Incentive Plan [Member] | |||||||||||||||||||||
| Share based compensation | $ | $ 99,000 | 146,000 | |||||||||||||||||||
| Stock option expenses | $ | $ 34,000 | 51,000 | |||||||||||||||||||
| Stock options reserved for future issuance | 617,839 | ||||||||||||||||||||
| Stock option exercise price | $ / shares | $ 0.705 | ||||||||||||||||||||
| Stock awards | $ | $ 65,000 | $ 95,000 | |||||||||||||||||||
| Stock issued, shares | 1,066,667 | ||||||||||||||||||||
| Stock issued, value | $ | $ 752,000 | ||||||||||||||||||||
| Vested shares | 1,066,667 | ||||||||||||||||||||
| Exercisable period | 10 years | ||||||||||||||||||||
| Restricted stock | |||||||||||||||||||||
| Stock option vested or to be vested, description | (1) 50% upon the first anniversary of the effective date and the remaining 50% upon the second anniversary of the effective date; (2) shares of the Company’s common stock close above $3.00 per share (as may be adjusted for any stock splits or similar actions); (3) the commencement of trading of shares of the Company’s common stock on a national securities exchange; | ||||||||||||||||||||
| Dr. Arthur Bertolino [Member] | On September 1, 2018 [Member] | |||||||||||||||||||||
| Share based compensation | $ | $ 164,000 | ||||||||||||||||||||
| Stock option expenses | $ | $ 57,000 | ||||||||||||||||||||
| Restricted shares issued | 533,334 | ||||||||||||||||||||
| Taxable share based compensation | $ | $ 87,140 | ||||||||||||||||||||
| Common stock shares issued | 314,387 | ||||||||||||||||||||
| Stock option vested or to be vested, description | vesting 50% upon the first anniversary of the grant date and 50% upon the second anniversary of the grant date, with acceleration in certain circumstances as provided in the award agreement. | ||||||||||||||||||||
| Stock options reserved for future issuance | 617,839 | ||||||||||||||||||||
| Stock option exercise price | $ / shares | $ 0.40 | ||||||||||||||||||||
| Stock issued, shares | 533,334 | ||||||||||||||||||||
| Stock issued, value | $ | $ 225,000 | ||||||||||||||||||||
| Vested shares | 533,334 | ||||||||||||||||||||
| Exercisable period | 10 years | ||||||||||||||||||||
| Stock awards | $ | $ 107,000 | ||||||||||||||||||||
| Closing stock price | 59.00% | ||||||||||||||||||||
| Remaining common stock shares withheld | $ | $ 218,946 | ||||||||||||||||||||
| Vesting percentage | 59.00% | ||||||||||||||||||||
| Ms. Anne Ponugoti [Member] | On September 1, 2018 [Member] | |||||||||||||||||||||
| Common stock shares issued | 5,000 | ||||||||||||||||||||
| Stock options reserved for future issuance | 5,000 | ||||||||||||||||||||
| Stock option exercise price | $ / shares | $ 0.40 | ||||||||||||||||||||
| Stock issued, shares | 5,000 | ||||||||||||||||||||
| Stock issued, value | $ | $ 2,000 | ||||||||||||||||||||
| Vested shares | 5,000 | ||||||||||||||||||||
| Proceeds from warrant exercises | $ | $ 540,000 | $ 540,000 | |||||||||||||||||||
| Consultant 1 [Member] | |||||||||||||||||||||
| Stock option vested or to be vested, description | These options were issued with an exercise price of $0.13 per share and vest 33 1/3% on February 1, 2019, 33 1/3% on August 1, 2019, and 33 1/3% on January 31, 2020 | ||||||||||||||||||||
| Stock options reserved for future issuance | 400,000 | ||||||||||||||||||||
| Stock option exercise price | $ / shares | $ 0.13 | ||||||||||||||||||||
| Consultant [Member] | On February 1, 2018 [Member] | Stock options [Member] | |||||||||||||||||||||
| Stock issued, shares | 75,000 | ||||||||||||||||||||
| Vested shares | 75,000 | ||||||||||||||||||||